Generated by AI
Adagene Inc. ADR is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company develops a platform of proprietary antibody technologies designed to improve the precision, safety, and effectiveness of biologic medicines, with current work centered on oncology and related immune-mediated diseases. Its product portfolio includes multiple investigational candidates in clinical development, reflecting a research-driven model that combines computational biology, antibody engineering, and translational science. Adagene Inc. ADR serves the healthcare and biotechnology markets by advancing differentiated therapeutic candidates aimed at complex cancers that remain difficult to treat with conventional approaches. As an ADR, the company provides investors with depositary-share exposure to its underlying business while remaining primarily identified with its biopharmaceutical operations in China.
WebsiteBuilding C14
Suzhou, 215123
China
The latest articles about ADAG.
Summary of Apr 2's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
Summary of Mar 12's posts. Generated by AI.
Investors talking about ADAG also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.